Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Multiple sclerosis

Natalizumab to fingolimod—the washout whitewash

A recent multicentre study has assessed the risk of relapse in patients with multiple sclerosis who switched from natalizumab to fingolimod treatment. Despite such efforts, no effective exit strategy from natalizumab treatment has yet been demonstrated for these patients.

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: Biological effects of natalizumab and fingolimod.

References

  1. Cohen, M. et al. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. JAMA Neurol. 71, 436–441 (2014).

    Article  Google Scholar 

  2. O'Connor, P. W. et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 76, 1858–1865 (2011).

    CAS  Article  Google Scholar 

  3. Jokubaitis, V. G. et al. Fingolimod after natalizumab and the risk of short-term relapse. Neurology 82, 1204–1211 (2014).

    CAS  Article  Google Scholar 

  4. Kappos, L. et al. Disease control and safety in relapsing–remitting multiple sclerosis (RRMS) patients switching from natalizumab to fingolimod: a 32-week, rater- and patient-blind, randomized, parallel-group study (TOFINGO). Mult. Scler. 19 (Suppl. 1), 50 (2013).

    Google Scholar 

  5. Bloomgren, G. et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366, 1870–1880 (2012).

    CAS  Article  Google Scholar 

  6. Krumbholz, M., Meinl, I., Kümpfel, T., Hohlfeld, R. & Meinl, E. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 71, 1350–1354 (2008).

    CAS  Article  Google Scholar 

  7. Kivisakk, P. et al. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology 72, 1922–1930 (2009).

    CAS  Article  Google Scholar 

  8. Fine, A. J., Sorbello, A., Kortepeter, C. & Scarazzini, L. Progressive multifocal leukoencephalopathy after natalizumab discontinuation. Ann. Neurol. 75, 108–115 (2014).

    CAS  Article  Google Scholar 

  9. Stüve, O. et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology 72, 396–401 (2009).

    Article  Google Scholar 

  10. Brinkmann, V. et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277, 21453–21457 (2002).

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Olaf Stüve.

Ethics declarations

Competing interests

M.S. has received honoraria or consultancy payments from Bayer Healthcare, Biogen Idec, Baxter, CSL Behring, Grifols, Merck-Serono, Novartis, Sanofi-Aventis, and Teva. His institution has received research support from Bayer Healthcare, Biogen Idec, Merck-Serono, Novartis, and Teva. O.S. declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Stangel, M., Stüve, O. Natalizumab to fingolimod—the washout whitewash. Nat Rev Neurol 10, 311–313 (2014). https://doi.org/10.1038/nrneurol.2014.82

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2014.82

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing